Skip to main content
SpringerLink
Log in

Indications for Autologous Stem Cell Transplant

  • Chapter
  • First Online:
Basics of Hematopoietic Stem Cell Transplant

Abstract

Autologous stem cell transplant (auto SCT) is a procedure where stem cells are mobilized and harvested and then the patient is treated with high-dose chemotherapy followed by rescue of marrow by the harvested stem cell. This procedure allows application of high doses of chemotherapy for tumor ablation which would not have been feasible without rescuing simultaneously ablated bone marrow. This characteristic property of bone marrow to regenerate completely after full myeloablation by the use of hematopoetic stem cells is unique and is the basis of stem cell transplantation, which is usually not seen in any other organ.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–25.

    Article  PubMed  Google Scholar 

  2. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Diffuse large B-cell lymphoma version 1.2016. J Natl Compr Cancer Netw JNCCN. 2016;14(2):196–231.

    Article  PubMed  Google Scholar 

  3. Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant. 2015;50(8):1037–56.

    Article  CAS  PubMed  Google Scholar 

  4. van Kampen RJW, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol. 2011;29(10):1342–8.

    Article  PubMed  Google Scholar 

  5. Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure—what to do? Hematol Am Soc Hematol Educ Program. 2016;2016(1):366–78.

    Article  Google Scholar 

  6. Vardhana SA, Sauter CS, Matasar MJ, Zelenetz AD, Galasso N, Woo KM, et al. Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. Br J Haematol. 2017;176(4):591–9.

    Article  CAS  PubMed  Google Scholar 

  7. Lekakis LJ, Moskowitz CH. The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma in the era of CAR-T cell therapy. Hemasphere. 2019;3(6):e295.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hamadani M, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, et al. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Adv. 2022;6(2):486–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sarkozy C, Traverse-Glehen A, Coiffier B. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. Lancet Oncol. 2015;16(15):e555–67.

    Article  CAS  PubMed  Google Scholar 

  10. Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(20):2260–7.

    Article  CAS  Google Scholar 

  11. Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, et al. Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. J Clin Oncol. 2017;35(1):24–31.

    Article  CAS  PubMed  Google Scholar 

  12. Li LR, Wang L, He YZ, Young KH. Current perspectives on the treatment of double hit lymphoma. Expert Rev Hematol. 2019;12(7):507–14.

    Article  CAS  PubMed  Google Scholar 

  13. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, et al. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2014;167(2):177–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, et al. Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(27):3293–9.

    Article  CAS  Google Scholar 

  15. Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood. 2009;113(5):995–1001.

    Article  CAS  PubMed  Google Scholar 

  16. Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 2006;108(8):2540–4.

    Article  CAS  PubMed  Google Scholar 

  17. Montoto S, Corradini P, Dreyling M, Ghielmini M, Kimby E, López-Guillermo A, et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica. 2013;98(7):1014–21.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Hamadani M, Horowitz MM. Allogeneic transplantation for follicular lymphoma: does one size fit all? J Oncol Pract. 2017;13(12):798–806.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Freedman A. Follicular lymphoma: 2015 update on diagnosis and management. Am J Hematol. 2015;90(12):1171–8.

    Article  CAS  PubMed  Google Scholar 

  20. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Non-Hodgkin’s lymphomas, version 4.2014. J Natl Compr Cancer Netw JNCCN. 2014;12(9):1282–303.

    Article  CAS  PubMed  Google Scholar 

  21. Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565–75.

    Article  CAS  PubMed  Google Scholar 

  22. Cohen JB, Zain JM, Kahl BS. Current approaches to mantle cell lymphoma: diagnosis, prognosis, and therapies. Am Soc Clin Oncol Educ Book. 2017;37:512–25.

    Article  PubMed  Google Scholar 

  23. Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014;32(4):273–81.

    Article  PubMed  Google Scholar 

  24. Hiddemann W, Unterhalt M, Herrmann R, Wöltjen HH, Kreuser ED, Trümper L, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol. 1998;16(5):1922–30.

    Article  CAS  PubMed  Google Scholar 

  25. Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250–60.

    Article  PubMed  Google Scholar 

  26. Kumar A, Eyre TA, Lewis KL, Thompson MC, Cheah CY. New directions for mantle cell lymphoma in 2022. Am Soc Clin Oncol Educ Book. 2022. [cited 9 Oct 2022]. https://ascopubs.org/doi/pdf/10.1200/EDBK_349509.

  27. Buege MJ, Kumar A, Dixon BN, Tang LA, Pak T, Orozco J, et al. Management of mantle cell lymphoma in the era of novel oral agents. Ann Pharmacother. 2020;54(9):879–98.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Rogers AM, Brammer JE. Hematopoietic cell transplantation and adoptive cell therapy in peripheral T-cell lymphoma. Curr Hematol Malig Rep. 2020;15(4):316–32.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Horwitz S, Ansell S, Barens J. T cell lymphoma, version 1.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2020;15(11):1–142.

    Google Scholar 

  30. Foster C, Kuruvilla J. Treatment approaches in relapsed or refractory peripheral T-cell lymphomas. F1000Research. 2020;9:F1000 Faculty Rev-1091.

    Google Scholar 

  31. Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, et al. ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24(4):857–77.

    Article  CAS  PubMed  Google Scholar 

  32. Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012;26(3):520–6.

    Article  CAS  PubMed  Google Scholar 

  33. Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2021;137(19):2646–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–71.

    Article  CAS  PubMed  Google Scholar 

  35. Van Den Neste E, Casasnovas O, André M, Touati M, Senecal D, Edeline V, et al. Classical Hodgkin’s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 2013;98(8):1185–95.

    Article  PubMed  Google Scholar 

  36. Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115(18):3671–7.

    Article  CAS  PubMed  Google Scholar 

  37. Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019;54(10):1525–52.

    Article  PubMed  Google Scholar 

  38. Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;9(4):1–10.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hemato-oncology and Bone Marrow Transplantation, Venkateshwar Hospital, New Delhi, Delhi, India

    Sanjeev Kumar Sharma

Authors
  1. Sanjeev Kumar Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sharma, S.K. (2023). Indications for Autologous Stem Cell Transplant. In: Basics of Hematopoietic Stem Cell Transplant. Springer, Singapore. https://doi.org/10.1007/978-981-19-5802-1_20

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-5802-1_20

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-5801-4

  • Online ISBN: 978-981-19-5802-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation